Clene to Present at the Canaccord 45th Annual Growth Conference
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments, will present at the Canaccord 45th Annual Growth Conference on August 12th, 2025, at 3:30pm ET in Boston, MA.
The company, which focuses on developing treatments for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), will conduct a presentation and host one-on-one investor meetings. A webcast will be available through the company's website and online registration.
Clene (NASDAQ: CLNN), un'azienda biofarmaceutica in fase clinica avanzata specializzata in trattamenti per malattie neurodegenerative, presenterà al Canaccord 45th Annual Growth Conference il 12 agosto 2025 alle 15:30 ET a Boston, MA.
L'azienda, focalizzata sullo sviluppo di terapie per la sclerosi laterale amiotrofica (SLA) e la sclerosi multipla (SM), terrà una presentazione e organizzerà incontri individuali con gli investitori. Una trasmissione in diretta sarà disponibile tramite il sito web dell'azienda e la registrazione online.
Clene (NASDAQ: CLNN), una empresa biofarmacéutica en etapa clínica avanzada especializada en tratamientos para enfermedades neurodegenerativas, presentará en la 45ª Conferencia Anual de Crecimiento Canaccord el 12 de agosto de 2025 a las 3:30 pm ET en Boston, MA.
La compañía, que se centra en desarrollar tratamientos para la esclerosis lateral amiotrófica (ELA) y la esclerosis múltiple (EM), realizará una presentación y llevará a cabo reuniones individuales con inversores. Habrá una transmisión web disponible a través del sitio web de la empresa y el registro en línea.
Clene (NASDAQ: CLNN)는 신경퇴행성 질환 치료제를 전문으로 하는 후기 임상 단계 바이오제약 회사로, 2025년 8월 12일 오후 3시 30분(동부시간)에 보스턴, MA에서 열리는 Canaccord 제45회 연례 성장 컨퍼런스에서 발표할 예정입니다.
이 회사는 근위축성 측삭 경화증(ALS)과 다발성 경화증(MS) 치료제 개발에 주력하고 있으며, 발표를 진행하고 1:1 투자자 미팅을 개최할 예정입니다. 웹캐스트는 회사 웹사이트와 온라인 등록을 통해 제공됩니다.
Clene (NASDAQ : CLNN), une société biopharmaceutique en phase clinique avancée spécialisée dans les traitements des maladies neurodégénératives, présentera lors de la 45e conférence annuelle sur la croissance Canaccord le 12 août 2025 à 15h30 ET à Boston, MA.
La société, qui se concentre sur le développement de traitements pour la sclérose latérale amyotrophique (SLA) et la sclérose en plaques (SEP), fera une présentation et organisera des rencontres individuelles avec des investisseurs. Une webdiffusion sera disponible via le site internet de la société et l'inscription en ligne.
Clene (NASDAQ: CLNN), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Behandlungen neurodegenerativer Erkrankungen spezialisiert hat, wird auf der Canaccord 45th Annual Growth Conference am 12. August 2025 um 15:30 Uhr ET in Boston, MA, präsentieren.
Das Unternehmen, das sich auf die Entwicklung von Therapien für amyotrophe Lateralsklerose (ALS) und multiple Sklerose (MS) konzentriert, wird eine Präsentation halten und Einzelgespräche mit Investoren führen. Ein Webcast wird über die Website des Unternehmens und die Online-Registrierung verfügbar sein.
- None.
- None.
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Canaccord 45th Annual Growth Conference and host 1x1 investor meetings.
Date: August 12th, 2025
Time of Presentation: 3:30pm ET
Location: Boston, MA
Format: Presentation
1x1 Meetings: Please contact your Canaccord representative
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When and where will Clene (CLNN) present at the Canaccord Growth Conference?
What diseases does Clene (CLNN) focus on treating?
How can investors access Clene's Canaccord conference presentation?
What type of meetings will Clene (CLNN) host at the Canaccord conference?
